Literature DB >> 36194724

ID-Checker Technology for the Highly Selective Macroscale Delivery of Anticancer Agents to the Cancer Cells.

Keum-Soo Song1, Satish Balasaheb Nimse2, Junghoon Kim1, Shrikant Dashrath Warkad1, Taisun Kim2.   

Abstract

Cancer cells deploy several glucose transport protein (GLUT) channels on the cell membranes to increase glucose uptake. Cancer cells die within 24 h in the absence of glucose. Thus, preventing the deployment of GLUT channels can deprive them of glucose, resulting in apoptosis within 24 h. Herein, we developed the ID-Checker with a glucose tag that ensures its highly specific macroscale delivery of anticancer agents to the cancer cells through the GLUT channels. ID-Checker presented here showed IC50 values of 0.17-0.27 and 3.34 μM in cancer and normal cell lines, respectively. ID-Checker showed a selectivity index of 12.5-20.2, which is about 10-20 times higher than that of known anticancer agents such as colchicine. ID-Checker inhibits the microtubule formation, which results in the prevention of the deployment of GLUT channels in 6 h and kills the cancer cells within 24 h without any damage to normal cells.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36194724      PMCID: PMC9575670          DOI: 10.1021/acs.jmedchem.2c00646

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   8.039


  40 in total

Review 1.  Microtubule-targeted anticancer agents and apoptosis.

Authors:  Kapil N Bhalla
Journal:  Oncogene       Date:  2003-12-08       Impact factor: 9.867

2.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

Review 3.  Microtubules as a target for anticancer drugs.

Authors:  Mary Ann Jordan; Leslie Wilson
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

4.  Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality.

Authors:  Denise A Chan; Patrick D Sutphin; Phuong Nguyen; Sandra Turcotte; Edwin W Lai; Alice Banh; Gloria E Reynolds; Jen-Tsan Chi; Jason Wu; David E Solow-Cordero; Muriel Bonnet; Jack U Flanagan; Donna M Bouley; Edward E Graves; William A Denny; Michael P Hay; Amato J Giaccia
Journal:  Sci Transl Med       Date:  2011-08-03       Impact factor: 17.956

5.  In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy.

Authors:  Rama K Mishra; Changyong Wei; Richard C Hresko; Richa Bajpai; Monique Heitmeier; Shannon M Matulis; Ajay K Nooka; Steven T Rosen; Paul W Hruz; Gary E Schiltz; Mala Shanmugam
Journal:  J Biol Chem       Date:  2015-04-06       Impact factor: 5.157

6.  What is the oncologic risk of stem cell treatment for heart disease?

Authors:  Konstantinos E Hatzistergos; Arnon Blum; Tan Ince; James M Grichnik; Joshua M Hare
Journal:  Circ Res       Date:  2011-05-27       Impact factor: 17.367

Review 7.  Cancer research: past, present and future.

Authors:  Ya Cao; Ronald A DePinho; Matthias Ernst; Karen Vousden
Journal:  Nat Rev Cancer       Date:  2011-09-15       Impact factor: 60.716

Review 8.  Expression of glucose transporters in cancers.

Authors:  Leszek Szablewski
Journal:  Biochim Biophys Acta       Date:  2012-12-21

9.  Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer.

Authors:  Suganthapriya Elayapillai; Satishkumar Ramraj; Doris Mangiaracina Benbrook; Magdalena Bieniasz; Lin Wang; Gopal Pathuri; Zitha Redempta Isingizwe; Amy L Kennedy; Yan D Zhao; Stanley Lightfoot; Lauri A Hunsucker; Camille C Gunderson
Journal:  Gynecol Oncol       Date:  2020-10-31       Impact factor: 5.482

10.  Controlled drug delivery vehicles for cancer treatment and their performance.

Authors:  Sudipta Senapati; Arun Kumar Mahanta; Sunil Kumar; Pralay Maiti
Journal:  Signal Transduct Target Ther       Date:  2018-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.